© 2019 Diligentia LLC

(202) 744-0755

January 8, 2020

In 2019, 44% of novel drugs approved in the U.S were classified with orphan designation.

60% of approved drugs fell into one or more expedited categories: Fast Track, Breakthrough, Priority Review, and/or Accelerated Approval.

  • But how does public conce...

December 2, 2019

If you are attending the J.P. Morgan Healthcare Conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

August 15, 2019

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

November 16, 2018

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

April 19, 2018

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

November 13, 2017

If you are attending the conference and would like to learn about how Diligentia can support your commercial business objectives, email us to arrange an on-site meeting: joff@diligentiastrategy.com

October 22, 2017

Joff Masukawa, Diligentia Strategy, will be the featured speaker at the November 3rd Virginia Bioscience Commercialization Luncheon. He will address commercialization strategies for biopharmaceuticals with a focus on the marketplace for rare diseases, orphan drugs, and...

April 5, 2017

Sen. Tom Cotton, R-Ark., is one of three GOP senators seeking an investigation into six-figure annual costs for drugs intended to treat rare diseases. Photo Credit: Alex Brandon/AP

The U.S. Government Accountability Office (GAO) will investigate potential abuse of the O...

March 20, 2017

The American Health Care Act, the bill intended to replace the Patient Protection and Affordable Care Act (ACA), is swiftly making its way through House Committees. Dubbed both Trumpcare and Ryancare, the draft bill consists of a number of legislative recommendations b...

Please reload

Recent Posts
  • LinkedIn Social Icon
Please reload